Chemomab Therapeutics
CMMB
14 hedge funds and large institutions have $606K invested in Chemomab Therapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
40% more funds holding
Funds holding: 10 → 14 (+4)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.58% less ownership
Funds ownership: 7.54% → 5.97% (-1.6%)
41% less capital invested
Capital invested by funds: $1.03M → $606K (-$420K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$275K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$212K |
| 3 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$137K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$50.4K |
| 5 |
VF
Virtu Financial
New York
|
+$29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$472K |
| 2 |
Morgan Stanley
New York
|
-$229K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$78.9K |
| 4 |
Jane Street
New York
|
-$15.7K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.9K |
CMMB Hedge Fund Activity: Q4 2025 in Review
14 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2025, worth a combined $606K — down 41% from $1.03M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CMMB positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $275K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $472K sold.
- 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2025, up from 10 in Q3 2025.
- Funds reported $606K of Chemomab Therapeutics stock for Q4 2025, down 41% quarter-over-quarter.
- 6 funds opened new Chemomab Therapeutics positions in Q4 2025 and 2 closed out, a net change of +4 holders.
- The largest Chemomab Therapeutics buyer in Q4 2025 was Citadel Advisors, an estimated $275K added.
- The largest Chemomab Therapeutics seller in Q4 2025 was Sphera Funds Management, an estimated $472K sold.
Based on aggregated 13F filings for Q4 2025.